Skip to main content
Protalix BioTherapeutics, Inc. logo

Protalix BioTherapeutics, Inc. — Investor Relations & Filings

Ticker · PLX ISIN · US74365A3095 LEI · 549300SDVB3GP4XDFM60 US Manufacturing
Open in API
Filings indexed 950 across all filing types
Latest filing 2020-04-22 Regulatory Filings
Country US United States of America
Listing US PLX

About Protalix BioTherapeutics, Inc.

https://protalix.com/

Protalix BioTherapeutics, Inc. is a biopharmaceutical company that develops, produces, and commercializes recombinant therapeutic proteins. The company's unique selling point is its proprietary ProCellEx® platform, a plant cell-based protein expression system used to manufacture complex proteins. This technology supports the development of treatments for rare and orphan diseases. Protalix has successfully brought enzyme replacement therapies to market and maintains a pipeline of product candidates targeting conditions with high unmet medical needs. The company's capabilities cover the entire process from protein candidate selection and genetic engineering of plant cells through preclinical and clinical development to commercial-scale production and marketing.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2020
Regulatory Filings Classification · 90% confidence The provided document text appears to be encoded or encrypted and does not contain any readable content, keywords, regulatory headers, or fiscal period dates that would allow identification of a specific filing type. There is no indication of report titles, financial data, or announcements. Given the lack of discernible information, the document cannot be classified into any specific category and defaults to the fallback category for miscellaneous filings.
2020-04-22 English
FORM S-3
Capital/Financing Update Classification · 100% confidence The document is a Form S-3 Registration Statement filed with the SEC, which is used for registering securities for sale to the public. It includes detailed information about the securities being registered, the offering process, and legal disclaimers. This type of filing is related to capital raising activities and financing, not a financial report, earnings release, or management discussion. The presence of registration fee calculations, offering price, and selling stockholders confirms it is a capital/financing update. Therefore, the document fits the Capital/Financing Update category (CAP). The document length and content confirm it is not a brief announcement or a report publication announcement but a full registration statement.
2020-04-17 English
DEF 14A
Proxy Solicitation & Information Statement
2020-04-15 English
OWNERSHIP DOCUMENT
Director's Dealing
2020-04-13 English
SC 13G
Major Shareholding Notification
2020-03-30 English
SC 13G
Major Shareholding Notification
2020-03-25 English

Browse filings by year

31 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.